ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Preventing Chronic Whiplash Pain

This study is currently recruiting patients.

Sponsored by: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

This study is aimed at developing ways to prevent acute pain from becoming chronic pain--specifically, pain associated with whiplash-associated disorders (WADs) from motor vehicle accidents. Research on the development of chronic pain due to musculoskeletal injury suggests that a person's initial emotional reactions, particularly fear of reinjury and subsequent avoidance of activity, contribute significantly to chronic pain and persistent disability. We will treat people with WADs during the first three months after a motor vehicle accident with a behavioral and physical exercise program designed to encourage activity and discourage continued fear of movement, pain, and disability. We will evaluate the effectiveness of two anxiety-reduction treatments compared to standard care in reducing pain and activity limitations in people with WADs in the 2-3 months following motor vehicle accidents.

Condition Treatment or Intervention Phase
Whiplash Injuries
 Behavior: Behavioral treatments
 Behavior: Physical therapy
Phase III

MedlinePlus related topics:  Neck Disorders and Injuries

Study Type: Interventional
Study Design: Prevention, Randomized, Single Blind, Active Control, Single Group Assignment, Safety Study

Official Title: Preventing Chronic Whiplash Pain: Biobehavioral Approach

Further Study Details: 

Expected Total Enrollment:  300

Study start: May 2001;  Study completion: March 2006

More than 1.8 million people in the United States suffer from chronic pain and disability following motor vehicle accidents (MVAs) each year. The majority of these cases start with a relatively minor neck injury. The Quebec Task Force Study on Whiplash Associated Disorders (WAD) was created in 1989 to determine the clinical, public health, social, and financial determinants of WAD. Multiple studies have described the clinical features of WAD, which include neck, shoulder, arm, low back, and head pain; tinnitus; visual symptoms; dizziness; temporomandibular joint pain; and paraesthesias. Onset of these symptoms after the injury is usually delayed for several hours and worsens within 24-48 hours. Neck pain is the most frequent symptom, and between 14% and 42% of patients with WAD develop chronic neck pain symptoms. Studies suggest that the neck pain will either resolve in the first few months or persist indefinitely. One variable that may predict outcome after an MVA is the acute emotional response immediately after the MVA.

A severe emotional reaction accompanied by neck pain and stiffness after an MVA could lead an injured person to avoid subsequent physical activity through such mechanisms as fear avoidance and fear of reinjury. Research investigating the evolution of chronic pain due to musculoskeletal injury suggests that initial emotional reactivity, particularly fear of reinjury and subsequent activity avoidance, contributes significantly to unremitting pain and persistent disability. Research based on this model has shown that early interventions targeting normalization of excessive emotionality and restriction of activities associated with fear following injury effectively prevent chronic pain due to back injury. No previous study has sought to intervene during the first three months after an MVA with a behavioral and physical exercise program to encourage activity and discourage continued fear of movement, pain and disability.

This study consists of two primary components: (1) We will evaluate the effectiveness of two anxiety-reduction treatments compared to standard care in reducing pain and activity limitations in patients with WADs 2-3 months following MVAs. (2) We will test whether psychological responses to the initial trauma such as fear avoidance, fear of injury, and negative affectivity discriminate between symptomatic WAD patients and WAD sufferers whose symptoms had resolved 2-3 months post-MVA.

Eligibility

Ages Eligible for Study:  20 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria


Location and Contact Information

Mary R. Aulet, MEd      206-543-3387    wads@u.washington.edu
Gretchen Langmaid      206-543-3387    wads@u.washington.edu

Washington
      University of Washington, Seattle,  Washington,  98195-6540,  United States; Recruiting
Dennis C. Turk, PhD  206-543-3387    wads@u.washington.edu 
Dennis C. Turk, PhD,  Principal Investigator

More Information

Click here for the WADS homepage.

Study ID Numbers:  NIAMS-064; R01 AR47298
Record last reviewed:  September 2004
Record first received:  July 16, 2001
ClinicalTrials.gov Identifier:  NCT00021476
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-08
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act